Live Breaking News & Updates on Molecular Therapeutics Price

Stay updated with breaking news from Molecular therapeutics price. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Buy" by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have earned a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock […] ....

United States , Scott Bizily , Healthcare Of Ontario Pension Plan Trust Fund , D Molecular Therapeutics Inc , Royal Bank , Goldman Sachs Group , Goldman Sachs Group Inc , Redmile Group , Vanguard Group Inc , Molecular Therapeutics , Get Free Report , Sachs Group , Ontario Pension Plan Trust Fund , Vanguard Group , Molecular Therapeutics Price , Get Free , Molecular Therapeutics Daily ,

Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,750 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $25.45, for a total value of $44,537.50. Following the sale, the insider now directly owns 1,737 shares of the […] ....

United States , Scott Bizily , D Molecular Therapeutics Company Profile , Goldman Sachs Group , Kennedy Capital Management , Jefferies Financial Group , D Molecular Therapeutics Inc , Royal Bank , Janus Henderson Group , Molecular Therapeutics , Get Free Report , Molecular Therapeutics Price , State Teachers Retirement System , Henderson Group , Molecular Therapeutics Company , Molecular Therapeutics Daily ,

Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $44.22

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Buy” by the ten research firms that are presently covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on […] ....

United States , Robert Young Kim , Scott Bizily , Goldman Sachs Group , D Molecular Therapeutics Inc , China Universal Asset Management Co , Royal Bank , Principal Financial Group Inc , Daiwa Securities Group Inc , Allspring Global Investments Holdings , Securities Exchange Commission , Molecular Therapeutics , Get Free Report , Molecular Therapeutics Price , Exchange Commission , Universal Asset Management , Global Investments Holdings , Securities Group , Principal Financial Group , Get Free , Molecular Therapeutics Daily , 4d Molecular Therapeutics , Nasdaq Fdmt ,

Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $44.22

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year […] ....

United States , Robert Young Kim , Scott Bizily , Vontobel Holding Ltd , Jefferies Financial Group , Royal Bank , D Molecular Therapeutics Company Profile , Goldman Sachs Group Inc , Securities Exchange Commission , Goldman Sachs Group , Sectoral Asset Management Inc , D Molecular Therapeutics Inc , Molecular Therapeutics , Get Free Report , Exchange Commission , Sachs Group , Sectoral Asset Management , Molecular Therapeutics Price , Molecular Therapeutics Company , Get Free , Molecular Therapeutics Daily , 4d Molecular Therapeutics , Nasdaq Fdmt ,